2016
Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT
Abdul-Rahim AH, Docherty KF, Skali H, Køber L, Dickstein K, Maggioni AP, Mareev V, Zannad F, Velazquez EJ, Califf RM, Pfeffer MA, Solomon SD, Lees KR, McMurray JJ. Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. European Stroke Journal 2016, 1: 93-100. PMID: 31008270, PMCID: PMC6301225, DOI: 10.1177/2396987316646025.Peer-Reviewed Original ResearchAngiotensin receptor blockersRisk of strokeAcute myocardial infarctionMyocardial infarctionReceptor blockersDual renin-angiotensin system blockadeEnzyme inhibitorsDual renin-angiotensin blockadeRenin-angiotensin system blockadeAcute Myocardial Infarction trialCox proportional hazards regressionRenin-angiotensin blockadeMyocardial Infarction trialRate of strokeVentricular systolic dysfunctionProportional hazards regressionRenin inhibitor aliskirenSystem blockadeSystolic dysfunctionHazard ratioHeart failureTreatment groupsPatientsDiabetesStroke
2006
The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M. The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal Of The American College Of Cardiology 2006, 47: 726-733. PMID: 16487836, DOI: 10.1016/j.jacc.2005.09.055.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina PectorisAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAtherosclerosisCaptoprilCardiovascular DiseasesDisease-Free SurvivalDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMyocardial InfarctionRandomized Controlled Trials as TopicRecurrenceStrokeTetrazolesValineValsartanConceptsAngiotensin receptor blockersAcute Myocardial Infarction trialMyocardial Infarction trialAtherosclerotic eventsMyocardial infarctionACE inhibitorsValsartan groupReceptor blockersEnzyme inhibitorsNon-fatal myocardial infarctionAngiotensin-converting enzyme inhibitorAnti-infarction effectSecondary preventive treatmentEffect of valsartanRenin-angiotensin systemBlood pressure differenceEffects of captoprilAcute myocardial infarctionCaptopril groupCombination groupPreventive treatmentLower riskEvidence gapsCaptoprilValsartan
2005
Left Ventricular Assessment in Myocardial Infarction: The VALIANT Registry
Hernandez AF, Velazquez EJ, Solomon SD, Kilaru R, Diaz R, O’Connor C, Ertl G, Maggioni AP, Rouleau JL, van Gilst W, Pfeffer MA, Califf RM. Left Ventricular Assessment in Myocardial Infarction: The VALIANT Registry. JAMA Internal Medicine 2005, 165: 2162-2169. PMID: 16217008, DOI: 10.1001/archinte.165.18.2162.Peer-Reviewed Original ResearchConceptsHeart failureMyocardial infarctionLV assessmentCardiac catheterizationVentricular assessmentAcute Myocardial Infarction RegistryAngiotensin-converting enzyme inhibitorClinical heart failureMyocardial Infarction RegistryLeft ventricular functionAcute myocardial infarctionQuality of careHospital mortalityHospital outcomesHospital stayBaseline characteristicsDischarge medicationsVentricular functionMultivariable modelPatientsPropensity analysisEnzyme inhibitorsLower mortalityCatheterizationEchocardiography
2000
Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design
Pfeffer M, McMurray J, Leizorovicz A, Maggioni A, Rouleau J, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers M, Velazquez E, Califf R, Investigators* F. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal 2000, 140: 727-750. PMID: 11054617, DOI: 10.1067/mhj.2000.108832.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IIAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilCause of DeathDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationHumansMulticenter Studies as TopicMyocardial InfarctionOdds RatioPatient SelectionProportional Hazards ModelsRandomized Controlled Trials as TopicResearch DesignSample SizeTetrazolesValineValsartanConceptsAngiotensin II receptor blockersII receptor blockersAcute myocardial infarctionMyocardial infarctionReceptor blockersVentricular dysfunctionHeart failureAngiotensin II receptor blocker valsartanEnzyme inhibitorsMajor nonfatal cardiovascular eventsAcute Myocardial Infarction trialAngiotensin-converting enzyme inhibitorDose of captoprilMultiple practice patternsNonfatal cardiovascular eventsUse of valsartanMyocardial Infarction trialReceptor blocker valsartanHigh-risk patientsLeft ventricular dysfunctionParallel-group studyRenin-angiotensin systemManagement of patientsCombination of captoprilLong-term treatment